Prosecution Insights
Last updated: April 19, 2026
Application No. 17/908,736

DRUG SOLUTION INJECTION NEEDLE AND DRUG SOLUTION INJECTION NEEDLE SYSTEM

Non-Final OA §112
Filed
Sep 01, 2022
Examiner
PONTON, JAMES D
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Japan Lifeline Co. Ltd.
OA Round
3 (Non-Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
435 granted / 546 resolved
+9.7% vs TC avg
Strong +35% interview lift
Without
With
+34.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
32 currently pending
Career history
578
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
38.5%
-1.5% vs TC avg
§102
18.5%
-21.5% vs TC avg
§112
34.7%
-5.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 546 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/4/26 has been entered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-7 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 has been amended to recite “…wherein the distal end member does not form ana conductor used to establish electrical contact with a nonmetallic part of a circuit. The disclosure as originally filed states “the distal end member being a sharp member and made of metal” (page 5 of specification) and “Any known metal used in drug solution injection needles can be used as the metal constituting the distal end member 10, with examples including stainless steel, NiTi, β titanium, and platinum iridium” (page 11 of specification). While it may be possible to perform procedures where the distal end member is not used as an electrode, it seems inaccurate to say that the distal end member does not form any electrode. In other words, it appears that because the distal end member is formed of metal, the distal end member is capable of being used as an electrode depending on how the drug solution injection needle is used. Therefore, it cannot be said for sure that the claim contains subject matter which was described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The examiner recommends amending the claim to clarify electrical connections of the drug solution injection needle (i.e. what the metal tube/electrode is connected to that allows it serve as an electrode, and how the distal end member is electrically isolated from specific components of the drug solution injection needle). Claims 2-7 are rejected as they depend from claim 1. Response to Arguments Applicant’s Remarks submitted 1/15/26 have been considered. While the examiner agrees with the Remarks concerning the previous prior art rejections, the amendments have resulted in the rejection under 35 U.S.C. 112(a) above. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to James D Ponton whose telephone number is (571)272-1001. The examiner can normally be reached M-F 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /James D Ponton/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Sep 01, 2022
Application Filed
Jun 24, 2025
Non-Final Rejection — §112
Sep 25, 2025
Response Filed
Oct 31, 2025
Final Rejection — §112
Jan 15, 2026
Response after Non-Final Action
Mar 04, 2026
Request for Continued Examination
Mar 10, 2026
Response after Non-Final Action
Mar 19, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599749
CONTROLLABLE INSERTION SLEEVE
2y 5m to grant Granted Apr 14, 2026
Patent 12599719
CLOSED SYSTEM ELASTOMERIC PUMPING MECHANISM
2y 5m to grant Granted Apr 14, 2026
Patent 12594376
COMPACT POSITIVE DISPLACEMENT PUMP FOR WEARABLE DRUG DELIVERY DEVICE
2y 5m to grant Granted Apr 07, 2026
Patent 12582768
MEDICAMENT DELIVERY SYSTEM, AND ASSOCIATED METHOD
2y 5m to grant Granted Mar 24, 2026
Patent 12582765
PUMP WITH PUMPING CHAMBER CREATED BY TELESCOPING ACTION DRIVEN BY FRICTION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+34.6%)
3y 0m
Median Time to Grant
High
PTA Risk
Based on 546 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month